Dr. Gary Feldman, Principal Investigator for the MRM-3379 Phase 2 clinical trial at the Irvine, California site, standing with an individual with Fragile X syndrome.

Recruiting: Mirum Launches Clinical Trial of MRM-3379 for Fragile X Syndrome

December 1, 2025

Mirum’s MRM-3379 Phase 2 trial builds on FRAXA-funded PDE4D research and is now enrolling males ages 13–45 with Fragile X syndrome. View eligibility and study sites.

Read More »

NPR Spotlights Zatolmilast: A Potential Breakthrough for Fragile X Syndrome

October 1, 2024

NPR spotlights zatolmilast, a promising investigational drug to treat Fragile X syndrome. Families report life-changing improvements in learning and independence.

Read More »

Categories

FRAXA Funded Research

Current Research Grants (45)